Skip to content

OUTCOME OF PATIENTS ADMITTED WITH ACUTE LOWER EXTREMITY ISCHEMIA

MULTICENTER OBSERVATIONAL STUDY OF THE OUTCOME OF PATIENTS ADMITTED WITH ACUTE LOWER EXTREMITY ISCHEMIA

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05255640
Acronym
DEVENIR-IAM
Enrollment
176
Registered
2022-02-24
Start date
2022-03-04
Completion date
2023-11-09
Last updated
2024-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemia of Lower Limb

Brief summary

Acute ischemia of the lower limb (AMI) is a life-threatening emergency that threatens the functional prognosis of the limb. Depending on the clinical presentation and the anatomy of the patient, several therapeutic approaches can be considered: open surgery, endovascular surgery, hybrid surgery or amputation if revascularization is not feasible. The data in the current literature do not allow to clearly establish which therapeutic approach is the most adapted to the patient.

Interventions

PROCEDUREoperation of ischemia of the lower limbs

The intervention technique is left to the judgment of the investigator to treat the ischemia

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age greater than 18 years, regardless of gender. * Diagnosis of AMI defined according to the Rutherford classification (2). AMI may involve one or both lower limbs. * Be able to understand and give free and informed consent (non-opposition) to participate in the study * To be affiliated to the social security system * Not to object to participating in the study (collection of non-objection)

Exclusion criteria

* Voluntary discharge of the patient: opposition to the use of the data (withdrawal of the non-objection) * Termination of the study by decision of the sponsor or investigator.

Design outcomes

Primary

MeasureTime frame
survival30 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026